Menu Search
Equities

Eiken Chemical Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
EKNCF:PKL

Eiken Chemical Co Ltd

Actions
  • Price (USD)--
  • Today's Change--
  • Shares traded--
  • 1 Year change--
  • Beta0.5308
Data delayed at least 15 minutes.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Eiken Chemical Co Ltd is a Japan-based company principally engaged in the manufacturing and sales of test drugs. Through its subsidiaries, the Company conducts contract the manufacturing of diagnostic reagents and purchases, manufactures and sells diagnostic reagents. The products and services include microbial testing reagents, urine testing reagents, immuno-serological test reagents, biochemical testing reagents and instrument food environment-related media. The Company sells its products in Japan and overseas markets.

  • Revenue in JPY (TTM)41.28bn
  • Net income in JPY3.83bn
  • Incorporated1939
  • Employees702.00
  • Location
    Eiken Chemical Co LtdYamaguchi Bldg.7, 4-19-9, TaitoTAITO-KU 110-8408JapanJPN
  • Phone+81 358463305
  • Fax+81 358463476
  • Websitehttps://www.eiken.co.jp/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.